Pharmacokinetics of ipriflavone, an isoflavone derivative, after intravenous and oral administration to rats - Hepatic and intestinal first-pass effects

被引:41
|
作者
Kim, SH
Lee, MG
机构
[1] Seoul Natl Univ, Coll Pharm, Kwanak Gu, Seoul 151742, South Korea
[2] Seoul Natl Univ, Pharmaceut Sci Res Inst, Seoul 151742, South Korea
[3] Kangnung Natl Univ, Coll Dent, Kangnung 210702, South Korea
关键词
ipriflavone; M1; M5; pharmacokinetics; hepatic first-pass effects; intestinal first pass effects; rats;
D O I
10.1016/S0024-3205(01)01508-9
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Pharmacokinetic parameters of ipriflavone were evaluated after intravenous administration of spray-dried ipriflavone with polyvinylpyrrolidone, SIP (5, 10, 20, and 40 mg/kg as ipriflavone) and oral administration of SIP (50, 100, and 200 mg/kg as ipriflavone) to rats. The hepatic, gastric, and intestinal first-pass effects of ipriflavone were also measured after intravenous, intraportal, intraduodenal, and oral administration of SIP (20 or 50 mg/kg as ipriflavone) to rats. After intravenous and oral administration, the pharmacokinetic parameters of ipriflavone were dose-independent. The extent of absolute oral bioavailability (F) was also independent of oral doses; the mean F value was approximately 24%. Considering the amount of unchanged ipriflavone recovered from 24-hr gastrointestinal tract (the mean value was approximately 12%), the low F values could be due to the hepatic, gastric, and/or intestinal first-pass effects. Based on total body clearance (CL) data of ipriflavone after intravenous administration, the first-pass effect in the heart and lung could be almost negligible, if any, in rats. Approximately 30% of ipriflavone absorbed into the portal vein was eliminated by liver (hepatic first-pass effect) based on intravenous and intraportal administration of SIP. The area under the plasma concentration-time curve from time zero to time infinity (AUC) values after oral administration and intraduodenal instillation of SIP, 50 mg/kg as ipriflavone, were not significantly different, but the values were significantly smaller (129 and 116 mug ml/min) than that after intraportal administration of SIP, 20 mg/kg as ipriflavone (513 mug ml/min based on 50 mg/kg), indicating that gastric first-pass effect of ipriflavone was negligible, but intestinal first-pass effect was considerable in rats. Therefore, the low F value of ipriflavone after oral administration to rats was mainly due to intestinal first-pass effect. The hepatic first-pass effect and incomplete absorption of ipriflavone from rat gastrointestinal tract could also contributed to the low F in rats. (C) 2002 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:1299 / 1315
页数:17
相关论文
共 50 条
  • [1] Pharmacokinetics of sildenafil after intravenous and oral administration in rats: Hepatic and intestinal first-pass effects
    Shin, Hyun S.
    Bae, Soo K.
    Lee, Myung G.
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2006, 320 (1-2) : 64 - 70
  • [2] Pharmacokinetics of DA-8159, a new erectogenic, after intravenous and oral administration to rats: Hepatic and intestinal first-pass effects
    Shim, HJ
    Kim, YC
    Park, KJ
    Kim, DS
    Kwon, JW
    Kim, WB
    Lee, MG
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2003, 92 (11) : 2185 - 2195
  • [3] Dose-dependent pharmacokinetics of itraconazole after intravenous or oral administration to rats: Intestinal first-pass effect
    Shin, JH
    Choi, KY
    Kim, YC
    Lee, MG
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (05) : 1756 - 1762
  • [4] Pharmacokinetics and tissue distribution of ipriflavone, an isoflavone derivative, after intravenous administration to rabbits
    Kim, SH
    Lee, JS
    Lee, MG
    BIOPHARMACEUTICS & DRUG DISPOSITION, 2000, 21 (04) : 147 - 156
  • [5] Pharmacokinetics of DA-7867, a new oxazolidinone, after intravenous or oral administration to rats: Intestinal first-pass effect
    Bae, SK
    Chung, WS
    Kim, EJ
    Rhee, JK
    Kwon, JW
    Kim, WB
    Lee, MG
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (02) : 659 - 662
  • [6] Pharmacokinetics of a chemoprotective agent, 2-(allylthio)pyrazine, after intravenous and oral administration to rats: Hepatic and gastric first-pass effects
    Han, KS
    Lee, MG
    DRUG METABOLISM AND DISPOSITION, 1999, 27 (02) : 221 - 226
  • [7] Pharmacokinetics of Hesperidin and its Hepatic, Gastric and Intestinal First-pass Effects in Rats
    Gu, Yingying
    Zhang, Xue
    Xie, Ming
    Tao, Xiaojun
    Zhang, Wenjie
    Zhang, Chungang
    Ying, Xixiang
    LATIN AMERICAN JOURNAL OF PHARMACY, 2019, 38 (08): : 1498 - 1504
  • [8] Dose-dependent pharmacokinetics of telithromycin after intravenous and oral administration to rats: Contribution of intestinal first-pass effect to low bioavailability
    Lee, Joo Hyun
    Lee, Myung Gull
    JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, 2007, 10 (01): : 37 - 50
  • [9] Hepatic and intestinal first-pass effects of Oltipraz in rats
    Bae, SK
    Kim, JW
    Kim, YH
    Kim, YG
    Kim, SG
    Lee, MG
    BIOPHARMACEUTICS & DRUG DISPOSITION, 2005, 26 (04) : 129 - 134
  • [10] Effect of Intestinal and Hepatic First-pass Extraction on the Pharmacokinetics of Everolimus in Rats
    Yokomasu, Akira
    Yano, Ikuko
    Sato, Eriko
    Masuda, Satohiro
    Katsura, Toshiya
    Inui, Ken-ichi
    DRUG METABOLISM AND PHARMACOKINETICS, 2008, 23 (06) : 469 - 475